1,979 research outputs found
Transfer of spectral weight across the gap of Sr2IrO4 induced by La doping
We study with Angle Resolved PhotoElectron Spectroscopy (ARPES) the evolution
of the electronic structure of Sr2IrO4, when holes or electrons are introduced,
through Rh or La substitutions. At low dopings, the added carriers occupy the
first available states, at bottom or top of the gap, revealing an anisotropic
gap of 0.7eV in good agreement with STM measurements. At further doping, we
observe a reduction of the gap and a transfer of spectral weight across the
gap, although the quasiparticle weight remains very small. We discuss the
origin of the in-gap spectral weight as a local distribution of gap values
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. Study PB-06-002 examined the safety and efficacy of taliglucerase alfa for 9 months in patients who previously received imiglucerase. The results of adult patients from Study PB-06-002 who continued receiving taliglucerase alfa in extension Study PB-06-003 for up to 36 months are reported here. Eighteen patients received at least one dose of taliglucerase alfa in Study PB-06-003; 10 patients completed 36 total months of therapy, and four patients who transitioned to commercial drug completed 30-33 months of treatment. In patients who completed 36 total months of treatment, mean percent (±standard error) changes from baseline/time of switch to taliglucerase alfa to 36 months were as follows: hemoglobin concentration, -1.0% (±1.9%; n = 10); platelet count, +9.3% (±9.8%; n = 10); spleen volume measured in multiples of normal (MN), -19.8% (±9.9%; n = 7); liver volume measured in MN, +0.9% (±5.4%; n = 8); chitotriosidase activity, -51.5% (±8.1%; n = 10); and CCL18 concentration, -36.5 (±8.0%; n = 10). Four patients developed antidrug antibodies, including one with evidence of neutralizing activity in vitro. All treatment-related adverse events were mild or moderate and transient. The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:661-665, 2016. © 2016 Wiley Periodicals, Inc
Genitourinary Syndrome of Menopause: Epidemiology, Physiopathology, Clinical Manifestation and Diagnostic
Genitourinary syndrome of menopause (GSM) is a term used to define a compilation of signs and symptoms arising from decreased estrogenic stimulation of the vulvovaginal and lower urinary tract. Among 27-84% of women in postmenopausal are affected for symptoms of GSM, and these can unquestionably impair health, sexual function, consequently the quality of life of these women. The main signs and symptoms of GSM include, among others, burning, irritation, vulvovaginal dryness, dyspareunia, urinary symptoms of urgency, dysuria, or recurrent urinary tract infection. The diagnosis can be made through anamnesis, questionnaires, physical exams, and, sometimes, complementary exams. Objective vaginal assessment is essential and can be complemented by using the Vaginal Health Index (VHI), Vaginal Maturation Index (VMI), or vaginal pH measurement. The acknowledgment of this condition by health professionals is crucial for its identification and proper management and exclusion of other conditions that make a differential diagnosis with it.info:eu-repo/semantics/publishedVersio
Propuesta didáctica para la enseñanza de la parábola en IngenierÃa Civil
Este artÃculo da cuenta de una experiencia en el aula de clase para la enseñanza de la parábola en estudiantes de IngenierÃa Civil de la Corporación Universitaria Minuto de Dios (UNIMINUTO) desarrollada durante el segundo semestre de 2004. En su diseño, se consideraron referentes pedagógicos y matemáticos que sirvieron como derroteros para la construcción de una propuesta metodológica donde el estudiante se enfrenta a situaciones muy similares a las que desarrollará en su vida profesional. Para la implementación se tuvieron en cuenta tres fases: contextualización, construcción y ampliación. Finalmente se presentan los resultados de la puesta en el aula desde tres aspectos: el trabajo de los estudiantes, la comprensión y la interacción didáctica, con las cuales se evidenció que para introducir la parábola a estudiantes de IngenierÃa Civil debe iniciarse con una situación problema, especÃfica de su futuro campo de acción, ya que de esta manera se motiva y se destaca la importancia de dicha cónica
Scale-invariant magnetoresistance in a cuprate superconductor
The anomalous metallic state in high-temperature superconducting cuprates is
masked by the onset of superconductivity near a quantum critical point. Use of
high magnetic fields to suppress superconductivity has enabled a detailed study
of the ground state in these systems. Yet, the direct effect of strong magnetic
fields on the metallic behavior at low temperatures is poorly understood,
especially near critical doping, . Here we report a high-field
magnetoresistance study of thin films of \LSCO cuprates in close vicinity to
critical doping, . We find that the metallic state
exposed by suppressing superconductivity is characterized by a
magnetoresistance that is linear in magnetic field up to the highest measured
fields of T. The slope of the linear-in-field resistivity is
temperature-independent at very high fields. It mirrors the magnitude and
doping evolution of the linear-in-temperature resistivity that has been
ascribed to Planckian dissipation near a quantum critical point. This
establishes true scale-invariant conductivity as the signature of the strange
metal state in the high-temperature superconducting cuprates.Comment: 10 pages, 3 figure
- …